Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2019
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
View Additional ASCO 2019 Converage on AHDB
Patient Navigators, Clinician Education Can Remove Barriers to Enrollment in Clinical Trials
By
Chase Doyle
Patient Navigation
,
Value-Based Care
,
Personalized Medicine
,
Economics & Value
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Fewer than 7% of adults with cancer and even fewer minority patients participate in clinical trials, which negatively affects the ability to determine the safety and efficacy of new and investigational therapies. At ASCO 2019, 2 experts discussed strategies to overcome the barriers to clinical trial participation and to help enroll more patients with cancer in them.
Read Article
Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL
In the Literature
,
Lymphoma
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
The 2 chimeric antigen receptor (CAR) T-cell therapies available so far—axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah)—may be considered cost-effective treatments for adults with diffuse large B-cell lymphoma (DLBCL), depending on the long-term outcomes of these patients, according to a recent cost-effective analysis (Lin JK, et al.
J Clin Oncol.
2019 Jun 3. Epub ahead of print).
Read Article
New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
Hematologic Malignancies
,
In the Literature
,
Multiple Myeloma
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Until recently, patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation (ASCT), the multiagent regimen with lenalidomide (Revlimid) and dexamethasone was the standard of care. Results of the prespecified interim analysis of the MAIA trial demonstrated the benefit of adding daratumumab (Darzalex) to this combination therapy (Facon T, et al.
N Engl J Med.
2019;380:2104-2115).
Read Article
FDA Unveils Oncology-Specific “Project Facilitate,” Expanding Access to Investigational Cancer Drugs
By
Phoebe Starr
Economics & Value
,
Value-Based Care
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—At ASCO 2019, the FDA announced an oncology-specific pilot program for physicians and patients who are seeking access to investigational therapies. The expanded access pilot program is a concierge service, said Richard Pazdur, MD, Director, FDA’s Oncology Center of Excellence, who spoke at a press conference where the new program—Project Facilitate—was announced.
Read Article
Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation
By
Phoebe Starr
Breast Cancer
,
In the Literature
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Approximately 40% of patients with hormone receptor (HR)-positive,
HER2
-negative breast cancer have mutations in the
PIK3CA
gene. Although endocrinebased therapy is the standard treatment, acquired resistance remains a challenge.
Read Article
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—BLU-667, a novel inhibitor of RET, elicited responses in more than 50% of patients with
RET
fusion–positive advanced non–small-cell lung cancer (NSCLC), according to data from an ongoing phase 1 clinical trial presented at ASCO 2019.
Read Article
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Expanded data from an early phase 1/2 clinical trial showed that treatment with repotrectinib, an investigational tyrosine kinase inhibitor (TKI) with potent selectivity against tumors with
ROS1
rearrangement, induced a response in 9 of 11 patients with TKI-naïve, advanced non–small-cell lung cancer (NSCLC) and
ROS1
fusion.
Read Article
Overcoming Current Barriers to Using CAR T-Cell Therapy in the Community Setting
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—With 475 cell and gene therapy companies in North America representing a business enterprise with approximately $20 billion, new immunotherapies are moving rapidly from the laboratory to the clinic. As chimeric antigen receptor (CAR) T-cell therapy makes its way from the academic to community setting, however, appropriate resources and infrastructure are required to ensure the safe and effective management of patients.
Read Article
Applying CAR T-Cell Therapies to Solid Tumors: Overcoming Current Challenges
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Reprogramming patients’ immune cells to treat their cancer has become the front line of cancer therapy, with chimeric antigen receptor (CAR) T-cell therapy now approved by the FDA for several blood cancers. But translating this success to solid tumors remains a challenge. At ASCO 2019, Gianpietro Dotti, MD, Cancer Cellular Immunotherapy Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, discussed efforts to extend the application of CAR T-cell therapy to solid tumors
Read Article
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
FDA Approvals, News & Updates
,
Lymphoma
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
On June 10, 2019, the FDA granted accelerated approval to polatuzumab vedotin-piiq (Polivy; Genentech), a CD79b-directed antibody–drug conjugate, in combination with bendamustine (Bendeka, Treanda) plus rituximab (Rituxan or a biosimilar), for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received ≥2 lines of therapy. The FDA granted polatuzumab breakthrough therapy and orphan drug designations.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma